Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 1, 2014, Pages 88-98

  Muniyan, Sakthivel ^a   Ingersoll, Matthew A ^a   Batra, Surinder K ^a,b   Lin, Ming Fong ^a,b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

CPAcP; ErbB 2; Phosphoinositide phosphatase; Prostate cancer; Protein tyrosine phosphatase; Tumor suppressor

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE DEACETYLASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B;

CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CARCINOGENICITY; ENZYME STRUCTURE; HUMAN; NONHUMAN; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

CPACP; ERBB-2; PHOSPHOINOSITIDE PHOSPHATASE; PROSTATE CANCER; PROTEIN TYROSINE PHOSPHATASE; TUMOR SUPPRESSOR;

ANIMALS; CARCINOGENESIS; EPITHELIUM; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN TYROSINE PHOSPHATASES; PTEN PHOSPHOHYDROLASE; SEQUENCE HOMOLOGY;

EID: 84905841664     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.04.006     Document Type: Review

References (154)

1. Bononi A., Agnoletto C., De Marchi E., Marchi S., Patergnani S., Bonora M., Giorgi C., Missiroli S., Poletti F., Rimessi A., Pinton P. Protein kinases and phosphatases in the control of cell fate. Enzyme Res. 2011, 2011:329098.
2. Motiwala T., Jacob S.T. Role of protein tyrosine phosphatases in cancer. Prog. Nucleic Acid Res. Mol. Biol. 2006, 81:297-329.
3. Tonks N.K. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 2006, 7:833-846.
4. Alonso A., Sasin J., Bottini N., Friedberg I., Friedberg I., Osterman A., Godzik A., Hunter T., Dixon J., Mustelin T. Protein tyrosine phosphatases in the human genome. Cell 2004, 117:699-711.
5. Veeramani S., Lee M.S., Lin M.F. Revisiting histidine-dependent acid phosphatases: a distinct group of tyrosine phosphatases. Trends Biochem. Sci. 2009, 34:273-278.
6. Zhang X.Q., Kondrikov D., Yuan T.C., Lin F.F., Hansen J., Lin M.F. Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene 2003, 22:6704-6716.
7. Yuan T.C., Veeramani S., Lin M.F. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr. Relat. Cancer 2007, 14:531-547.
8. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.
9. Sharifi N., Gulley J.L., Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 2005, 294:238-244.
10. Madan R.A., Pal S.K., Sartor O., Dahut W.L. Overcoming chemotherapy resistance in prostate cancer. Clin. Cancer Res. 2011, 17:3892-3902.
11. Muniyan S., Chaturvedi N.K., Dwyer J.G., Lagrange C.A., Chaney W.G., Lin M.F. Human prostatic acid phosphatase: structure, function and regulation. Int. J. Mol. Sci. 2013, 14:10438-10464.
12. Chuang T.D., Chen S.J., Lin F.F., Veeramani S., Kumar S., Batra S.K., Tu Y., Lin M.F. Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth. J. Biol. Chem. 2010, 285:23598-23606.
13. Drake J.M., Graham N.A., Stoyanova T., Sedghi A., Goldstein A.S., Cai H., Smith D.A., Zhang H., Komisopoulou E., Huang J., Graeber T.G., Witte O.N. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:1643-1648.
14. Tricoli J.V., Gumerlock P.H., Yao J.L., Chi S.G., D'Souza S.A., Nestok B.R., deVere White R.W. Alterations of the retinoblastoma gene in human prostate adenocarcinoma. Gene Chromosome Cancer 1996, 15:108-114.
15. Sharma A., Yeow W.S., Ertel A., Coleman I., Clegg N., Thangavel C., Morrissey C., Zhang X., Comstock C.E., Witkiewicz A.K., Gomella L., Knudsen E.S., Nelson P.S., Knudsen K.E. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J. Clin. Invest. 2010, 120:4478-4492.
16. Sun H., Wang Y., Chinnam M., Zhang X., Hayward S.W., Foster B.A., Nikitin A.Y., Wills M., Goodrich D.W. E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:704-709.
17. Isaacs W.B., Carter B.S., Ewing C.M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 1991, 51:4716-420.
18. Massenkeil G., Oberhuber H., Hailemariam S., Sulser T., Diener P.A., Bannwart F., Schäfer R., Schwarte-Waldhoff I. P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer. Anticancer Res. 1994, 14:2785-2790.
19. Heidenberg H.B., Sesterhenn I.A., Gaddipati J.P., Weghorst C.M., Buzard G.S., Moul J.W., Srivastava S. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol. 1995, 154:414-421.
20. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
21. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H., Tavtigian S.V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 1997, 15:356-362.
22. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J.G., Jen J., Isaacs W.B., Bova G.S., Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 1997, 57:4997-5000.
23. Feilotter H.E., Nagai M.A., Boag A.H., Eng C., Mulligan L.M. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998, 16:1743-1748.
24. Deocampo N.D., Huang H., Tindall D.J. The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol. 2003, 28:145-153.
25. Mulholland D.J., Dedhar S., Wu H., Nelson C.C. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene 2006, 25:329-337.
26. Lin M.F., Lee M.S., Zhou X.W., Andressen J.C., Meng T.C., Johansson S.L., West W.W., Taylor R.J., Anderson J.R., Lin F.F. Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells. J. Urol. 2001, 166:1943-1950.
27. Veeramani S., Yuan T.C., Chen S.J., Lin F.F., Petersen J.E., Shaheduzzaman S., Srivastava S., MacDonald R.G., Lin M.F. Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr. Relat. Cancer 2005, 12:805-822.
28. Quintero I.B., Araujo C.L., Pulkka A.E., Wirkkala R.S., Herrala A.M., Eskelinen E.L., Jokitalo E., Hellstrom P.A., Tuominen H.J., Hirvikoski P.P., Vihko P.T. Prostatic acid phosphatase is not a prostate specific target. Cancer Res. 2007, 67:6549-6554.
29. Quintero I.B., Herrala A.M., Araujo C.L., Pulkka A.E., Hautaniemi S., Ovaska K., Pryazhnikov E., Kulesskiy E., Ruuth M.K., Soini Y., Sormunen R.T., Khirug L., Vihko P.T. Transmembrane prostatic acid phosphatase (TMPAP) interacts with snapin and deficient mice develop prostate adenocarcinoma. PLoS One 2013, 8:e73072.
30. Singh A.P., Bafna S., Chaudhary K., Venkatraman G., Smith L., Eudy J.D., Johansson S.L., Lin M.F., Batra S.K. Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett. 2008, 259:28-38.
31. Bhardwaj A., Singh S., Srivastava S.K., Honkanen R.E., Reed E., Singh A.P. Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications. Mol. Cancer Ther. 2011, 10:720-731.
32. Pandey P., Seshacharyulu P., Das S., Rachagani S., Ponnusamy M.P., Yan Y., Johansson S.L., Datta K., Lin M.F., Batra S.K. Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway. Br. J. Cancer 2013, 108:2590-2600.
33. Seshacharyulu P., Pandey P., Datta K., Batra S.K. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett. 2013, 335:9-18.
34. Patel R., Gao M., Ahmad I., Fleming J., Singh L.B., Rai T.S., McKie A.B., Seywright M., Barnetson R.J., Edwards J., Sansom O.J., Leung H.Y. Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. J. Clin. Invest. 2013, 123:1157-1175.
35. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., Arora V.K., Kaushik P., Cerami E., Reva B., Antipin Y., Mitsiades N., Landers T., Dolgalev I., Major J.E., Wilson M., Socci N.D., Lash A.E., Heguy A., Eastham J.A., Scher H.I., Reuter V.E., Scardino P.T., Sander C., Sawyers C.L., Gerald W.L. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
36. Chen M., Pratt C.P., Zeeman M.E., Schultz N., Taylor B.S., O'Neill A., Castillo-Martin M., Nowak D.G., Naguib A., Grace D.M., Murn J., Navin N., Atwal G.S., Sander C., Gerald W.L., Cordon-Cardo C., Newton A.C., Carver B.S., Trotman L.C. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell 2011, 20:173-186.
37. Newton A.C., Trotman L.C. Turning off AKT: PHLPP as a drug target. Annu. Rev. Pharmacol. Toxicol. 2014, 54:537-558.
38. Davies G., Jiang W.G., Mason M.D. The interaction between beta-catenin, GSK3beta and APC after motogen induced cell-cell dissociation, and their involvement in signal transduction pathways in prostate cancer. Int. J. Oncol. 2001, 18:843-847.
39. Enokida H., Shiina H., Urakami S., Igawa M., Ogishima T., Li L.C., Kawahara M., Nakagawa M., Kane C.J., Carroll P.R., Dahiya R. Multigene methylation analysis for detection and staging of prostate cancer. Clin. Cancer Res. 2005, 11:6582-6588.
40. Richiardi L., Fiano V., Grasso C., Zugna D., Delsedime L., Gillio-Tos A., Merletti F. Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer. PLoS One 2013, 8:e68162.
41. Edwards S.M., Evans D.G., Hope Q., Norman A.R., Barbachano Y., Bullock S., Kote-Jarai Z., Meitz J., Falconer A., Osin P., Fisher C., Guy M., Jhavar S.G., Hall A.L., O'Brien L.T., Gehr-Swain B.N., Wilkinson R.A., Forrest M.S., Dearnaley D.P., Ardern-Jones A.T., Page E.C., Easton D.F., Eeles R.A. UK Genetic Prostate Cancer Study Collaborators and BAUS Section of Oncology, Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br. J. Cancer 2010, 103:918-924.
42. Pasche B., Yi N. Candidate gene association studies: successes and failures. Curr. Opin. Genet. Dev. 2010, 20:257-261.
43. Dechsukhum C., Ware J.L., Ferreira-Gonzalez A., Wilkinson D.S., Garrett C.T. Detection of a novel truncated WT1 transcript in human neoplasia. Mol. Diagn. 2000, 5:117-128.
44. Devilard E., Bladou F., Ramuz O., Karsenty G., Dalès J.P., Gravis G., Nguyen C., Bertucci F., Xerri L., Birnbaum D. FGFR1 and WT1 are markers of human prostate cancer progression. BMC Cancer 2006, 6:272.
45. Tycko B., Li C.M., Buttyan R. The Wnt/beta-catenin pathway in Wilms tumors and prostate cancers. Curr. Mol. Med. 2007, 7:479-489.
46. Vihko P. Human prostatic acid phosphatases: purification of a minor enzyme and comparisons of the enzymes. Invest. Urol. 1979, 16:349-352.
47. Van Etten R.L. Human prostatic acid phosphatase: a histidine phosphatase. Ann. N. Y. Acad. Sci. 1982, 390:27-51.
48. Lin M.F., Lee C.L., Li S.S., Chu T.M. Purification and characterization of a new human prostatic acid phosphatase isoenzyme. Biochemistry 1983, 22:1055-1062.
49. Goldfarb D.A., Stein B.S., Shamszadeh M., Petersen R.O. Age-related changes in tissue levels of prostatic acid phosphatase and prostate specific antigen. J. Urol. 1986, 136:1266-1269.
50. Yam L.T. Clinical significance of the human acid phosphatases: a review. Am. J. Med. 1974, 56:604-616.
51. Cunha A.C., Weigle B., Kiessling A., Bachmann M., Rieber E.P. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett. 2006, 236:229-238.
52. Graddis T.J., McMahan C.J., Tamman J., Page K.J., Trager J.B. Prostatic acid phosphatase expression in human tissues. Int. J. Clin. Exp. Pathol. 2011, 4:295-306.
53. Gutman E.B., Sproul E.E., Gutman A.B. Significance of increased phosphatase activity at the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am. J. Cancer 1936, 28:485-495.
54. Huggins C., Hodges C.V. Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941, 1:293-297.
55. Papsidero L.D., Wojcieszyn J.W., Horoszewicz J.S., Leong S.S., Murphy G.P., Chu T.M. Isolation of prostatic acid phosphatase-binding immunoglobulin G from human sera and its potential for use as a tumor-localizing reagent. Cancer Res. 1980, 40:3032-3035.
56. Wang M.C., Valenzuela L.A., Murphy G.P., Chu T.M. Purification of a human prostate specific antigen. Invest. Urol. 1979, 17:159-163.
57. Chu T.M., Lin M.F. PSA and acid phosphatase in the diagnosis of prostate cancer. J. Clin. Lig. Assay 1998, 21:24-34.
58. Igawa T., Lin F.F., Rao P., Lin M.F. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase. Prostate 2003, 55:247-258.
59. Vihko P.T., Quintero I., Ronka A.E., Herrala A., Jantti P., Porvari K., Lindqvist Y., Kaija H., Pulkka A., Vuoristo J., Sormunen R., Soini Y., Halmekytö M., Jänne J., Luokkala T., Kurkela R. Prostatic acid phosphatase (PAcP) is PI(3)P-phosphatase and its inactivation leads to change of cell polarity and invasive prostate cancer. Proc. Am. Assoc. Cancer Res. 2005, 46:5239.
60. Sharief F.S., Lee H., Leuderman M.M., Lundwall A., Deaven L.L., Lee C.L., Li S.S. Human prostatic acid phosphatase: cDNA cloning, gene mapping and protein sequence homology with lysosomal acid phosphatase. Biochem. Biophys. Res. Commun. 1989, 160:79-86.
61. Sharief F.S., Li S.S. Structure of human prostatic acid phosphatase gene. Biochem. Biophys. Res. Commun. 1992, 184:1468-1476.
62. Drenckhahn D., Waheed A., van Etten R. Demonstration of prostatic-type acid phosphatase in non-lysosomal granules in the crypt epithelium of the human duodenum. Histochemistry 1987, 88:47-52.
63. Risley M.J., Van Etten R.L. Structures of the carbohydrate moieties of human prostatic acid phosphatase elucidated by 1H nuclear magnetic resonance spectroscopy. Arch. Biochem. Biophys. 1987, 258:404-412.
64. Hakalahti L., Vihko P., Henttu P., Autio-Harmainen H., Soini Y., Vihko R. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. Int. J. Cancer 1993, 55:590-597.
65. Kuciel R., Bakalova A., Mazurkiewicz A., Bilska A., Ostrowski W. Is the subunit of prostatic phosphatase active? Reversible denaturation of prostatic acid phosphatase. Biochem. Int. 1990, 22:329-334.
66. Jakob C.G., Lewinski K., Kuciel R., Ostrowski W., Lebioda L. Crystal structure of human prostatic acid phosphatase. Prostate 2000, 42:211-218.
67. Luchter-Wasylewska E. Cooperative kinetics of human prostatic acid phosphatase. Biochim. Biophys. Acta 2001, 1548:257-264.
68. Van Etten R.L., Davidson R., Stevis P.E., MacArthur H., Moore D.L. Covalent structure, disulfide bonding, and identifi cation of reactive surface and active site residues of human prostatic acid phosphatase. J. Biol. Chem. 1991, 266:2313-2319.
69. Schneider G., Lindqvist Y., Vihko P. Three-dimensional structure of rat acid phosphatase. EMBO J. 1993, 12:2609-2615.
70. Ostanin K., Saeed A., van Etten R.L. Heterologous expression of human prostatic acid phosphatase and site-directed mutagenesis of the enzyme active site. J. Biol. Chem. 1994, 269:8971-8978.
71. Zhang X.Q., Lee M.S., Zelivianski S., Lin M.F. Characterization of a prostate-specific tyrosine phosphatase by mutagenesis and expression in human prostate cancer cells. J. Biol. Chem. 2001, 276:2544-2550.
72. Porvari K.S., Herrala A.M., Kurkela R.M., Taavitsainen P.A., Lindqvist Y., Schneider G., Vihko P.T. Site-directed mutagenesis of prostatic acid phosphatase. Catalytically important aspartic acid 258, substrate specificity, and oligomerization. J. Biol. Chem. 1994, 269:22642-22646.
73. Ortlund E., LaCount M.W., Lebioda L. Crystal structures of human prostatic acid phosphatase in complex with a phosphate ion and alpha-benzylaminobenzylphosphonic acid update the mechanistic picture and offer new insights into inhibitor design. Biochemistry 2003, 42:383-389.
74. Lad P.M., Learn D.B., Cooper J.F., Reisinger D.M. Distribution of prostatic acid phosphatase isoenzymes in normal and cancerous states. Clin. Chim. Acta 1984, 141:51-65.
75. Foti A.G., Cooper J.F., Herschman H. Prostatic acid phosphatase and prostatic cancer. Recent Results Cancer Res. 1979, 67:45-49.
76. Ronnberg L., Vihko P., Sajanti E., Vihko R. Clomiphene citrate administration to normogonadotropic subfertile men: blood hormone changes and activation of acid phosphatase in seminal fluid. Int. J. Androl. 1981, 4:372-378.
77. Lin M.F., Garcia-Arenas R., Xia X.Z., Biela B., Lin F.F. The cellular level of prostatic acid phosphatase and the growth of human prostate carcinoma cells. Differentiation 1994, 57:143-149.
78. Lin M.F., Garcia-Arenas R. Effect of cell density on androgen regulation of the mRNA level of human prostatic acid phosphatase. Mol. Cell. Endocrinol. 1994, 99:R21-R24.
79. Solin T., Kontturi M., Pohlmann R., Vihko P. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses. Biochim. Biophys. Acta 1990, 1048:72-77.
80. Reif A.E., Schlesinger R.M., Fish C.A., Robinson C.M. Acid phosphatase isozymes in cancer of the prostate. Cancer 1973, 31:689-699.
81. Lin M.F., Meng T.C., Rao P.S., Chang C., Schonthal A.H., Lin F.F. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J. Biol. Chem. 1998, 273:5939-5947.
82. Meng T.C., Lee M.S., Lin M.F. Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene 2000, 19:2664-2677.
83. Mori K., Wakasugi C. Immunocytochemical demonstration of prostatic acid phosphatase: different secretion kinetics between normal, hyperplastic and neoplastic prostates. J. Urol. 1985, 133:877-883.
84. Lilja H., Abrahamsson P.A. Three predominant proteins secreted by the human prostate gland. Prostate 1988, 12:29-38.
85. Sinha A.A., Gleason D.F., Wilson M.J., Wick M.R., Reddy P.K., Blackard C.E. Relationship of prostatic acid phosphatase localization in human prostate by a monoclonal antibody with the Gleason grading system. Prostate 1988, 13:1-15.
86. Seitz J., Aumüller G. Cytochemistry and biochemistry of acid phosphatases V: electrophoretic studies on the heterogeneity of acid phosphatases from human prostate, seminal fluid, and leukocytes. Prostate 1985, 7:73-90.
87. Lam K.W., Li C.Y., Yam L.T., Sun T., Lee G., Ziesmer S. Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody. Prostate 1989, 15:13-21.
88. Dionne F.T., Chevalier S., Bleau G., Roberts K.D., Chapdelaine A. Induction of acid phosphatase synthesis in canine prostatic epithelial cells in vitro. Mol. Cell. Endocrinol. 1983, 33:113-126.
89. Lin M.F., DaVolio J., Garcia-Arenas R. Expression of human prostatic acid phosphatase activity and the growth of prostate carcinoma cells. Cancer Res. 1992, 52:4600-4607.
90. Igawa T., Lin F.F., Lee M.S., Karan D., Batra S.K., Lin M.F. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 2002, 50:222-235.
91. Yuan T.C., Lin F.F., Veeramani S., Chen S.J., Earp H.S., Lin M.F. ErbB-2 via PYK2 upregulates the adhesive ability of androgen receptor-positive human prostate cancer cells. Oncogene 2007, 26:7552-7559.
92. Lin M.F., DaVolio J., Garcia R. Cationic liposome-mediated incorporation of prostatic acid phosphatase protein into human prostate carcinoma cells. Biochem. Biophys. Res. Commun. 1993, 192:413-419.
93. Lin M.F., Meng T.C. Tyrosine phosphorylation of a 185kDa Phosphoprotein (pp 185) inversely correlates with the cellular activity of human prostatic acid phosphatase. Biochem. Biophys. Res. Commun. 1996, 226:206-213.
94. Chou Y.W., Chaturvedi N.K., Ouyang S., Lin F.F., Kaushik D., Wang J., Kim I., Lin M.F. Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. Cancer Lett. 2011, 311:177-186.
95. Foti A.G., Herschman H., Cooper J.F. Isozymes of acid phosphatase in normal and cancerous human prostatic tissue. Cancer Res. 1977, 37:4120-4124.
96. Loor R., Wang M.C., Valenzuela L., Chu T.M. Expression of prostatic acid phosphatase in human prostate cancer. Cancer Lett. 1981, 14:63-69.
97. Dillard P.R., Lin M.F., Khan S.A. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol. Cell. Endocrinol. 2008, 295:115-120.
98. Svensson R.U., Haverkamp J.M., Thedens D.R., Cohen M.B., Ratliff T.L., Henry M.D. Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer. Am. J. Pathol. 2011, 179:502-512.
99. Roy-Burman P., Wu H., Powell W.C., Hagenkord J., Cohen M.B. Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr. Relat. Cancer 2004, 11:225-254.
100. Zylka M.J., Sowa N.A., Taylor-Blake B., Twomey M.A., Herrala A., Voikar V., Vihko P. Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine. Neuron 2008, 60:111-122.
101. Choe B.K., Lillehoj H.S., Dong M.K., Gleason S., Barron M., Rose N.R. Characterization of antigenic sites of human prostatic acid phosphatase. Ann. N. Y. Acad. Sci. 1982, 390:16-26.
102. Wasylewska E., Czubak J., Ostrowski W.S. Phosphoprotein phosphatase activity of human prostate acid phosphatase. Acta Biochim. Pol. 1983, 30:175-184.
103. Lin M.F., Clinton G.M. Human prostatic acid phosphatase has phosphotyrosyl protein phosphatase activity. Biochem. J. 1986, 235:351-357.
104. Chevalier S., Landry D., Chapdelaine A. Phosphotyrosine phosphatase activity of human and canine acid phosphatases of prostatic origin. Prostate 1988, 12:209-219.
105. Lin M.F., Clinton G.M. Human prostatic acid phosphatase and its phosphotyrosylprotein phosphatase activity. Adv. Protein Phosphatases 1987, 4:199-228.
106. Vihko P., Virkkunen P., Henttu P., Roiko K., Solin T., Huhtala M.L. Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Lett. 1988, 236:275-281.
107. Roiko K., Janne O.A., Vihko P. Primary structure of rat secretory acid phosphatase and comparison to other acid phosphatases. Gene 1990, 89:223-229.
108. Jackson M.D., Denu J.M. Molecular reactions of protein phosphatases-insights from structure and chemistry. Chem. Rev. 2001, 101:2313-2340.
109. Li H.C., Chernoff J., Chen L.B., Kirschonbaum A. A phosphotyrosyl-protein phosphatase activity associated with acid phosphatase from human prostate gland. Eur. J. Biochem. 1984, 138:45-51.
110. Vihko P., Kurkela R., Porvari K., Herrala A., Lindfors A., Lindqvist Y., Schneider G. Rat acid phosphatase: overexpression of active, secreted enzyme by recombinant baculovirus-infected insect cells, molecular properties, and crystallization. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:799-803.
111. Craft N., Shostak Y., Carey M., Sawyers C.L. Mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 1999, 5:280-285.
112. Yeh S., Lin H.K., Kang H.Y., Thin T.H., Lin M.F., Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:5458-5463.
113. Lin M.F., Clinton G.M. The epidermal growth factor receptor from prostate cells is dephosphorylated by a prostate-specific phosphotyrosyl phosphatase. Mol. Cell. Biol. 1988, 8:5477-5485.
114. Meng T.C., Lin M.F. Tyrosine phosphorylation of c-ErbB-2 is regulated by the cellular form of prostatic acid phosphatase in human prostate cancer cells. J. Biol. Chem. 1998, 273:22096-22104.
115. Di Lorenzo G., Tortora G., D'Armiento F.P., De Rosa G., Staibano S., Autorino R., D'Armiento M., De Laurentiis M., De Placido S., Catalano G., Bianco A.R., Ciardiello F. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res. 2002, 8:3438-3444.
116. Lee M.S., Igawa T., Yuan T.C., Zhang X.Q., Lin F.F., Lin M.F. ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells. Oncogene 2003, 22:781-796.
117. Ricciardelli C., Jackson M.W., Choong C.S., Stahl J., Marshall V.R., Horsfall D.J., Tilley W.D. Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate 2008, 68:830-838.
118. Soler M., Mancini F., Meca-Cortes O., Sánchez-Cid L., Rubio N., López-Fernández S., Lozano J.J., Blanco J., Fernández P.L., Thomson T.M. HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells. Int. J. Cancer 2009, 125:2565-2575.
119. Veeramani S., Chou Y.W., Lin F.C., Muniyan S., Lin F.F., Kumar S., Xie Y., Lele S.M., Tu Y., Lin M.F. Reactive oxygen species induced by p66Shc longevity protein mediate nongenomic androgen action via tyrosine phosphorylation signaling to enhance tumorigenicity of prostate cancer cells. Free Radic. Biol. Med. 2012, 53:95-108.
120. Veeramani S., Igawa T., Yuan T.C., Lin F.F., Lee M.S., Lin J.S., Johansson S.L., Lin M.F. Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells. Oncogene 2005, 24:7203-7212.
121. Chen S.J., Karan D., Johansson S.L., Lin F.F., Zeckser J., Singh A.P., Batra S.K., Lin M.F. Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells. Prostate 2007, 67:557-571.
122. Radhakrishnan P., Chachadi V., Lin M.F., Singh R., Kannagi R., Cheng P.W. TNFα enhances the motility and invasiveness of prostatic cancer cells by stimulating the expression of selective glycosyl- and sulfotransferase genes involved in the synthesis of selectin ligands. Biochem. Biophys. Res. Commun. 2011, 409:436-441.
123. Sharma S., Pirila P., Kaija H., Porvari K., Vihko P., Juffer A.H. Theoretical investigations of prostatic acid phosphatase. Proteins 2005, 58:295-308.
124. Pulido R., Stoker A.W., Hendriks W.J. PTPs emerge as PIPs: protein tyrosine phosphatases with lipid-phosphatase activities in human disease. Hum. Mol. Genet. 2013, 22:R66-R76.
125. Lin H.K., Hu Y.C., Yang L., Altuwaijri S., Chen Y.T., Kang H.Y., Chang C. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J. Biol. Chem. 2003, 278:50902-50907.
126. Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012, 13:283-296.
127. Steelman L.S., Bertrand F.E., McCubrey J.A. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opin. Ther. Targets 2004, 8:537-550.
128. Li L., Ross A.H. Why is PTEN an important tumor suppressor?. J. Cell. Biochem. 2007, 102:1368-1374.
129. Gericke A., Munson M., Ross A.H. Regulation of the PTEN phosphatase. Gene 2006, 374:1-9.
130. Chalhoub N., Baker S.J. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 2009, 4:127-150.
131. Janssens V., Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 2001, 353:417-439.
132. Mayer-Jaekel R.E., Hemmings B.A. Protein phosphatase 2A - a 'menage a trois'. Trends Cell Biol. 1994, 4:287-291.
133. Kamibayashi C., Estes R., Lickteig R.L., Yang S.I., Craft C., Mumby M.C. Comparison of heterotrimeric protein phosphatase 2A containing different B subunits. J. Biol. Chem. 1994, 269:20139-20148.
134. Cohen P.T. Novel protein serine/threonine phosphatases: variety is the spice of life. Trends Biochem. Sci. 1997, 22:245-251.
135. Arnold H.K., Sears R.C. Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol. Cell. Biol. 2006, 26:2832-2844.
136. Eichhorn P.J., Creyghton M.P., Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim. Biophys. Acta 2009, 1795:1-15.
137. Kuo Y.C., Huang K.Y., Yang C.H., Yang Y.S., Lee W.Y., Chiang C.W. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J. Biol. Chem. 2008, 283:1882-1892.
138. Cheng Y., Liu W., Kim S.T., Sun J., Lu L., Sun J., Zheng S.L., Isaacs W.B., Xu J. Evaluation of PPP2R2A as a prostate cancer susceptibility gene: a comprehensive germline and somatic study. Cancer Genet. 2011, 204:375-381.
139. Warfel N.A., Newton A.C. Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling. J. Biol. Chem. 2012, 287:3610-3616.
140. Brognard J., Sierecki E., Gao T., Newton A.C. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol. Cell 2007, 25:917-931.
141. Carrión-Salip D., Panosa C., Menendez J.A., Puig T., Oliveras G., Pandiella A., DeLlorens R., Massaguer A. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Int. J. Oncol. 2012, 41:1128-1138.
142. Chen L., Mooso B.A., Jathal M.K., Madhav A., Johnson S.D., van Spyk E., Mikhailova M., Zierenberg-Ripoll A., Xue L., Vinall R.L., deVere White R.W., Ghosh P.M. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin. Cancer Res. 2011, 17:6218-6228.
143. Jain A., Penuel E., Mink S., Schmidt J., Hodge A., Favero K., Tindell C., Agus D.B. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res. 2010, 70:1989-1999.
144. van Niekerk C.C., Poels L.G. Reduced expression of protein tyrosine phosphatase gamma in lung and ovarian tumors. Cancer Lett. 1999, 137:61-73.
145. Longo F.M., Martignetti J.A., Le Beau J.M., Zhang J.S., Barnes J.P., Brosius J. Leukocyte common antigen-related receptor-linked tyrosine phosphatase. Regulation of mRNA expression. J. Biol. Chem. 1993, 268:26503-26511.
146. Broggini M., Buraggi G., Brenna A., Riva L., Codegoni A.M., Torri V., Lissoni A.A., Mangioni C., D'Incalci M. Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res. 2000, 20:4835-4840.
147. Lee J.K., Edderkaoui M., Truong P., Ohno I., Jang K.T., Berti A., Pandol S.J., Gukovskaya A.S. NADPH oxidase promotes pancreatic cancer cell survival via inhibiting JAK2 dephosphorylation by tyrosine phosphatases. Gastroenterology 2007, 133:1637-1648.
148. Paul M.K., Mukhopadhyay A.K. Tyrosine kinase-role and significance in cancer. Int. J. Med. Sci. 2004, 1:101-115.
149. Wang Z., Shen D., Parsons D.W., Bardelli A., Sager J., Szabo S., Ptak J., Silliman N., Peters B.A., van der Heijden M.S., Parmigiani G., Yan H., Wang T.L., Riggins G., Powell S.M., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., Velculescu V.E. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004, 304:1164-1166.
150. Georgescu M.M. PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer 2010, 1:1170-1177.
151. Slomovitz B.M., Coleman R.L. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin. Cancer Res. 2012, 18:5856-5864.
152. Hafsi S., Pezzino F.M., Candido S., Ligresti G., Spandidos D.A., Soua Z., McCubrey J.A., Travali S., Libra M. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance. Int. J. Oncol. 2012, 40:639-644.
153. Demicco E.G., Torres K.E., Ghadimi M.P., Colombo C., Bolshakov S., Hoffman A., Peng T., Bovée J.V., Wang W.L., Lev D., Lazar A.J. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod. Pathol. 2012, 25:212-221.
154. Dillon L.M., Miller T.W. Therapeutic targeting of cancers with loss of PTEN function. Curr. Drug Targets 2014, 15:65-79.